Clinical trials
catalyst calendar across sponsors →Studies where GUTS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 observational · 3 with posted results
Held by 7 tracked-famous managers (MAVERICK CAPITAL LTD, JANE STREET GROUP, LLC, MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, +2 more) · FINRA short interest 1.8 days to cover (settled 2026-07-31) · insider 90d: 5 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on TirzepatideNCT06484114To demonstrate that Revita DMR is superior to sham in percent change in body weight from baseline to week 26Randomized · Triple-masked · Prevention | Not applicable | Active, not recruiting | Device: Revita Duodenal Mucosal Resurfacing (DMR), Sham | Obesity, Weight Change Trajectory, Weight Change, Body | 315 | 2027-02-15 | in 180 d | 2026-03-03 |
| A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 DiabetesNCT06256497observationalClinical effectiveness | — | Suspendedsponsor's stated reason: The company paused enrollment due to a strategic decision to pause commercialization in the EU and specifically Germany. The company will follow currently enrolled subjects per protocol. | Device: Duodenal Mucosal Resurfacing (DMR) | Diabetes Mellitus, Type 2 | 100 | 2028-07-01 | in 682 d | 2025-03-14 |
| Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 DiabetesNCT04419779Demonstrate superiority of Revita DMR to sham in improving glycemic controlRandomized · Quadruple-masked · Treatment | Not applicable | Suspendedsponsor's stated reason: Enrollment pause | Device: Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham) | Type 2 Diabetes | 320 | Jan 2026 | — | 2025-11-13 |
| Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 DiabetesNCT03653091results2022-07-26Change in Hemoglobin A1c (HbA1c)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing Sham (Sham) | Type 2 Diabetes | 9 | 2020-08-10actual | — | 2024-02-14 |
| Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)NCT02879383results2021-05-25Change From Baseline at 24 Weeks in Hemoglobin A1c (HbA1c), DMR vs Sham.Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Procedure: DMR Procedure, Sham Procedure | Diabetes Mellitus, Type 2, Noninsulin-Dependent Diabetes Mellitus | 109 | 2019-12-20actual | — | 2024-02-14 |
| Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 DiabetesNCT02413567mean reduction in HbA1c (glycated hemoglobin) from baseline at 24 weeks post-procedureOpen-label · Treatment | Not applicable | Completed | Device: DMR Procedure (Fractyl) | Diabetes Mellitus, Type 2, Diabetes Mellitus | 60 | 2017-06-12actual | — | 2024-02-14 |
| Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 DiabetesNCT01927562results2020-03-24Changed in Mixed Meal Tolerance From Baseline to 3 MonthsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Fractyl Duodenal Remodeling System | Type II Diabetes | 57 | 2017-04-07actual | — | 2024-02-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19